Long Shortz with Neurotech: Dual strategy positions NTI164 for autism and Rett markets

Host Tylah Tully speaks with Neurotech International (ASX:NTI) CEO Anthony Filippis about the company’s recent progress with its lead drug candidate NTI164, a unique cannabinoid therapy targeting paediatric neurological disorders such as autism spectrum disorder and Rett syndrome.

Filippis highlights multiple achievements, including the completion of non-clinical toxicology studies showing no safety concerns, and a Phase 1 pharmacokinetic study confirming strong oral absorption without accumulation.

These data are now feeding into regulatory dossiers. Importantly, Neurotech has secured orphan drug designation for NTI164 in Rett syndrome from both the US FDA and the European Medicines Agency, granting valuable financial incentives and market exclusivity of seven years in the US and ten in Europe.

Watch the video to learn more.

This video was developed in collaboration with Neurotech International, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.